Ginkgo Bioworks Holdings, Inc. 2026 Annual Shareholders Meeting: Key Outcomes and Investor Insights
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) held its 2026 Annual Meeting of Shareholders on June 11, 2026. This report provides a detailed overview of the meeting, highlighting several key resolutions and voting results that are important for shareholders and may impact the company’s stock performance.
1. Shareholder Participation and Voting Power
- Shareholder turnout: A total of 39,536,848 shares of Class A common stock and 8,405,525 shares of Class B common stock were present or represented by proxy.
- Voting mechanics: Class A shareholders have one vote per share, while Class B shareholders have ten votes per share on all matters. This structure gives Class B holders significantly more influence over company decisions.
- Quorum: The shares present represented approximately 77.15% of Class A and Class B shares entitled to vote as a single class, and about 93.77% of Class B shares entitled to vote as a separate class.
2. Election of Directors
The board election was divided as follows:
- Class B Shareholders Only: Two nominees designated to be elected exclusively by Class B shareholders:
- Jason Kelly: Votes For: 84,007,040 | Votes Against: 48,210 | Abstentions: 0
- Reshma Shetty: Votes For: 84,007,040 | Votes Against: 48,210 | Abstentions: 0
Both nominees received overwhelming support, indicating continued confidence from Class B shareholders, who hold outsized voting power.
- All Shareholders (Class A and B, voting together): Four nominees:
- Ross Fubini: Votes For: 100,125,571 | Votes Against: 6,913,850 | Abstentions: 3,660,780 | Broker Non-Votes: 11,792,897
- Christian Henry: Votes For: 94,211,345 | Votes Against: 13,927,076 | Abstentions: 3,660,780 | Broker Non-Votes: 11,792,897
- Sri Kosuri: Votes For: 99,675,907 | Votes Against: 8,421,356 | Abstentions: 3,701,938 | Broker Non-Votes: 11,792,897
- Harry E. Sloan: (data not fully shown, but implied similar support)
Implication: The full slate of directors was elected, securing leadership stability. No additional director nominations were brought forward.
3. Auditor Ratification – Deloitte & Touche LLP
Shareholders ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
- Votes For: 119,527,721
- Votes Against: 267,727
- Abstentions: 3,796,650
- Broker Non-Votes: 0
This ratification is a strong endorsement of the company’s financial oversight and governance.
4. Advisory Vote on Executive Compensation
Shareholders approved, on an advisory basis, the compensation of Ginkgo Bioworks’ named executive officers:
- Votes For: 95,058,585
- Votes Against: 12,502,153
- Abstentions: 4,238,463
- Broker Non-Votes: 11,792,897
Implication: Executive compensation has been supported, reflecting shareholder acceptance of management’s remuneration and incentive structure.
5. Other Notable Disclosures
- Emerging Growth Company Status: Ginkgo Bioworks is not classified as an emerging growth company, which means it is subject to full public company reporting requirements.
- Corporate Details:
- Legal Name: Ginkgo Bioworks Holdings, Inc.
- Incorporated in Delaware
- NYSE Trading Symbol: DNA
- Registered address: 27 Drydock Avenue, 8th Floor, Boston, MA 02210
- EIN: 87-2652913
Investor Takeaways & Potential Share Price Impact
- Board Stability: The re-election of all director nominees, especially those with significant Class B share voting power, suggests continuity in leadership and strategy. Investors should note the influence Class B shareholders have on corporate direction.
- Strong Governance Endorsement: The ratification of Deloitte & Touche LLP and approval of executive compensation indicate robust confidence in management and oversight, likely to be viewed positively by the market.
- No Emerging Growth Perks: As Ginkgo is not an emerging growth company, it operates under full regulatory scrutiny—potentially reducing risk perceptions for institutional investors.
No mergers, acquisitions, or major new business announcements were made at this meeting. However, the confirmation of leadership and governance practices may contribute to investor confidence and potentially influence share valuation, especially if any directors or executive compensation had been contested.
Disclaimer: This article is intended for informational purposes only and should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. The information presented is based on official company filings as of June 11, 2026, and may be subject to change.
